Two New Boosted-PI Coformulations
Topic:
Publish Date:
Wednesday, February 4, 2015
The FDA has approved two new PI-boosted coformulations: darunavir + cobicstat, and atazanavir + cobicstat.
Bug Chasers: Gay Men and the Intentional Pursuit of HIV - A Narrative Analysis
Topic:
Publish Date:
Wednesday, February 4, 2015
Imagine you are sitting down with a dear friend that you haven’t seen in years because he ran away from an unloving, unsupportive home, from a town where he was different, picked on, and knew he could never be safe - at least that is how he felt, - to a place where he would find love, and the supportive family he so dearly wanted. He discloses that he is gay and living with HIV infection. He says not to worry, that it’s ok, and then he says, “There’s more.” You feel your heart beat faster and time suspends.
iCare: Evaluating the Usability of iPad Minis in the Clinical Setting
Topic:
Publish Date:
Wednesday, January 7, 2015
Technology is great…when it works. This phrase comes to mind every time technology is supposed to enhance an experience and a malfunction causes that experience to cease. We know that technology should have the capacity to transform our lives, including our lives as HIV care providers. But in order for it to do so, it has to work. It has to be usable (i.e. easy, reliable, and fast). While iPad Minis have been on the market for several years now, a review of the literature yielded no current studies to examine their usability or effectiveness in clinical use.
The HIV/AIDS Treatment Cascade in the U.S. Virgin Islands: Testing and Diagnosis in Paradise
Publish Date:
Wednesday, December 3, 2014
Quite often when you think about the U.S. Virgin Islands (USVI), you envision a beautiful vacation on the beach drinking Pina Coladas, eating local food and listening to the sounds of island music. Although the Virgin Islands are truly paradise vacation spots, they are not free from the impact of HIV/AIDS. The three islands of St. Croix, St. Thomas, and St. John are unique and face their own challenges with testing, diagnosis, and treatment.
The National Quality Center Highlights Innovative Tools as it Celebrates its 10-Year Anniversary
Topic:
Publish Date:
Tuesday, December 16, 2014
In order to curtail new HIV infections and better reach—and engage—people living with HIV into care, providers have to evolve in the way that they do business. Performance measures are important indicators in ensuring effective provider practices and high-quality HIV care.
For the last 10 years the National Quality Center (NQC) has provided technical assistance to support Ryan White HIV/AIDS Program grantees by creating innovative services to meet their unique needs.
Connecting to Care: How Ryan White Grantees are Engaging Patients with the ACA
Topic:
Publish Date:
Friday, November 14, 2014
It’s that time of the year again: open enrollment season within the Health Insurance Marketplace!
Ryan White HIV/AIDS Program grantees are actively engaged in Affordable Care Act (ACA) activities, connecting patients with health insurance—many for the first time in their lives. The transformative power of health insurance cannot be overstated, particularly for individuals with a chronic disease like HIV and whom often times suffer from a myriad of other health conditions.
Drug-Drug Interactions: Etravirine with Dolutegravir or Atazanavir
Publish Date:
Friday, October 17, 2014
New data show that etravirine (ETR) substantially lowers plasma concentrations of dolutegravir (DTG) (DTG Cmin decreased 88%, AUC decreased 71%). This effect is lessened by coadministration of ritonavir-boosted PIs: the combination of ETR + DTG + darunavir/ritonavir (600/100 mg BID) resulted in a decrease in DTG Cmin and AUC of 37% and 25%, respectively. When ETR + DTG were given with lopinavir/ritonavir, the DTG Cmin and AUC were increased slightly. No data are available for the interaction with atazanavir/ritonavir.
The Jawbone is Connected to All Bones: Bisphosphonate-related Osteonecrosis of the Jaw (BRONJ)
Topic:
Publish Date:
Wednesday, October 8, 2014
Bisphosphonates medications (Fosamax, Boniva, Alendronate) are commonly used in the treatment of bone diseases such as osteoporosis, Paget disease, and multiple myeloma, and to limit bone pain and hypercalcemia associated with malignant metastatic bone lesions.
Elvitegravir Approved as an Independent Medication
Topic:
Publish Date:
Friday, September 26, 2014
Elvitegravir is an HIV integrase inhibitor that requires pharmacokinetic enhancement with cobicistat or ritonavir. Since 2012 it has been available in a coformulation with cobicistat, tenofovir, and emtricitabine (Stribild) for treatment-naïve adults. This month the FDA approved elvitegravir as an independent medication, for use in in combination with a ritonavir-boosted protease inhibitor (and other ARVs) in treatment-experienced adults. Its brand name is Vitekta.
Cobicistat approved as PK booster
Topic:
Publish Date:
Friday, September 26, 2014
Cobicistat, a CYP3A inhibitor, has been approved by the FDA to be used as a pharmacokinetic booster for atazanavir and once-daily darunavir. Thus, it can be used as an alternative to ritonavir in these combinations. It already is available as a PK enhancer of elvitegravir in the elvitegravir/cobicistat/tenofovir/emtricitabine coformulation (Stribild). Cobicistat’s brand name is Tybost.
Pages
